Evidence map›Paper›PMID 36687386›Full record

ReviewTherapeutic advances in medical oncology2023

New developments in targeted therapy for metastatic colorectal cancer.

Ambrose H N Wong, Brigette Ma, Rashid N Lui

Open access · goldAbstract readReview
In one paragraph

Review in Therapeutic advances in medical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Expression Analysis ofIranian journal of medical sciences · 2026
    Article
  5. Article
  6. Targeted apoptotic immune modulator for the treatment of metastatic EGFR-positive solid tumors.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  7. Article
  8. Review
  9. Structure-Activity Relationship Study of (ACS pharmacology & translational science · 2024
    Article
  10. Review
  11. Exploring the Therapeutic Potential ofCurrent drug discovery technologies · 2024
    Article
  12. Clinical research progress on BRAF V600E-mutant advanced colorectal cancer.Journal of cancer research and clinical oncology · 2023
    Review
  13. Article
  14. 3International journal of molecular sciences · 2023
    Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 2 countries.

Ambrose H N WongFaculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.ORCID https://orcid.org/0000-0002-8039-2643
Brigette MaState Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute, Hong Kong SAR, China.ORCID https://orcid.org/0000-0003-4802-1102
Rashid N LuiDepartment of Clinical Oncology, and Division of Gastroenterology and Hepatology, Department of Medicine and Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong, 9/F, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, China.
Chinese University of Hong Kong · HK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is the second most lethal cancer worldwide and the prognosis of metastatic CRC (mCRC) remains poor. Recent advancements in translational research have led to the identification of several new therapeutic targets and improved the treatment outcome of patients with tumours harbouring

Indexed as

BRAF inhibitorcolorectal cancerEGFR inhibitorpersonalized medicineprecision oncologytargeted therapy

Identifiers

PMID36687386
PMCPMC9846305
OpenAlexW4316465387

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.